SCHEMBL17599385

SCHEMBL17599385

Cc1nn(C)c(C)c1S(=O)(=O)Nc1ccc(-c2cc(C(=O)O)ccc2F)c2ccccc12

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.47
ACLY P53396 4/20 0.43
PTK2B Q14289 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
FABP4 P15090 3/20 0.43
TTR P02766 1/20 0.41
LMNA P02545 1/20 0.41
MAPK1 P28482 1/20 0.41
SLC16A3 O15427 1/20 0.39
MAPT P10636 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
KMT2A Q03164 1/20 0.38
RAD52 P43351 1/20 0.37
FABP5 Q01469 1/20 0.37
NMT1 P30419 1/20 0.37
CCR2 P41597 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17599305 0.92 ACLY (0.55) TSHRACLYPTK2BSMN1; SMN2FABP4
SCHEMBL17599320 0.90 SMN1; SMN2 (0.54) ACLYPTK2BSMN1; SMN2FABP4LMNA
SCHEMBL17599388 0.85 ACLY (0.48) TSHRACLYSMN1; SMN2LMNAMAPK1
SCHEMBL17613353 0.85 FABP4 (0.38) ACLYPTK2BSMN1; SMN2FABP4LMNA
SCHEMBL17599370 0.83 ALDH1A1 (0.53) ACLYPTK2BSMN1; SMN2FABP4SLC16A3
SCHEMBL17599341 0.81 FABP4 (0.43) ACLYPTK2BSMN1; SMN2FABP4SLC16A3
SCHEMBL17599338 0.79 FABP4 (0.42) ACLYPTK2BSMN1; SMN2FABP4SLC16A3
SCHEMBL17599412 0.79 FABP4 (0.45) ACLYPTK2BSMN1; SMN2FABP4SLC16A3
SCHEMBL17599392 0.79 CCKBR (0.47) ACLYPTK2BSMN1; SMN2FABP4SLC16A3
SCHEMBL17599355 0.78 PTK2B (0.43) ACLYPTK2BSMN1; SMN2FABP4SLC16A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2998294-A1 Naphthyl sulfonamide phenyl derivatives as KEAP-1 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders SANOFI (FR) 2016-03-23 EP claimed
EP-2998294-A1 Naphthyl sulfonamide phenyl derivatives as KEAP-1 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders SANOFI (FR) 2016-03-23 EP disclosed